Risankizumab: Daily Practice Experience of High Need Patients

Psoriasis is a chronic inflammatory disease which affects 29.5 million people worldwide and it can negatively impact quality of life, especially when it affects a special localization, such as nails, face, palms and soles, or intertriginous regions. Risankizumab is a humanized monoclonal antibody which targets the p19 subunit of interleukin-23 and it is currently licensed also as systemic therapy for moderate to severe plaque psoriasis. Here, we present eight cases of patients with moderate to severe psoriasis treated with risankizumab with a significant efficacy in the remission of the disease. Our cases represent a real-world clinical setting and provide a valuable adjunct to results obtained in the selected patients usually included in controlled clinical trials. In our cases, risankizumab rapidly improved clinical manifestations and relieved symptoms in patients with moderate to severe psoriasis, regardless of the presence of comorbidities or the location of the plaques in special sites, and without any safety concerns.

Automated summary

Psoriasis is a chronic inflammatory disease that affects 29.5 million people worldwide, causing negative impact on quality of life when it affects specific areas. Risankizumab, a humanized monoclonal antibody, effectively treats moderate to severe psoriasis by targeting interleukin-23. Our real-world cases demonstrate the efficacy of risankizumab in improving clinical manifestations and relieving symptoms, without safety concerns.